Sotevtamab clinical trials
How each study uses sotevtamab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the sotevtamab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
4 studies that test it; most in 2015 (1)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2021 | 1 |
| 2024 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Alethia Biotherapeutics (3) · ImmunityBio, Inc. (1)
Often tested with
Tested in the same studies.
Folfox protocol (1) · Nogapendekin alfa inbakicept (1) · Zabadinostat (1) · Albumin-Bound Paclitaxel (1) · Paclitaxel (1) · Gemcitabine (1)
Studies
Open first, then newest update. How each study uses sotevtamab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Sotevtamab (AB-16B5) Combined With FOLFOX as Neoadjuvant Treatment Prior to Resection of Colorectal Cancer Liver MetastasisRecruitingPhase 2Alethia BiotherapeuticsNCT06225843Written as Sotevtamab
- Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic CancerWithdrawnPhase 1ImmunityBio, Inc.NCT07488884Written as Sotevtamab
- AB-16B5 Combined With Docetaxel in Subjects With Metastatic Non-Small Cell Lung Cancer (EGIA-002)CompletedPhase 2Alethia BiotherapeuticsNCT04364620Written as AB-16B5
- Phase I Dose Escalation Study of AB-16B5 in Subjects With an Advanced Solid MalignancyCompletedPhase 1Alethia BiotherapeuticsNCT02412462Written as AB-16B5
Codes
What other systems call sotevtamab · ClinicalTrials.gg INT018610
- UNII (FDA) YQ3YJK67AFSOTEVTAMABOne source FDA
- NCI Thesaurus C121778SotevtamabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | YQ3YJK67AF | SOTEVTAMAB | One source FDA |
| NCI Thesaurus | C121778 | Sotevtamab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.